| Management target | Revenue 10.0% FY27 |
|---|
| Revenue growth | 22% YoY growth to 80.2 billion INR, driven by India and US. |
|---|---|
| Margins | EBITDA margin at 24.1%, targeting 24% despite higher specialty R&D. |
| Demand visibility | Strong traction in chronic therapies and new specialty launches in US. |
| Management confidence | High, emphasizing transition toward an innovation-led, specialty-driven business model. |
Growth
Consolidated revenue grew 22% YoY to 80.2 billion INR; EBITDA margins remained healthy at 24.1%.
Outlook
Management guides for strong double-digit revenue growth and maintained 24% EBITDA margins for FY27.
Risks
Higher operating costs from Assertio integration and Saro marketing spend may pressure short-term margins.
Last quarter's promises, checked
Delivered
- Guided 24% plus EBITDA margin → delivered 24.1% (= BEAT)
- Guided double-digit revenue growth → delivered 22% (= BEAT)
- Guided India outperformance vs IPM → delivered 20% growth (= BEAT)
Partly delivered
- Guided FY27 capex 15bn INR → current run-rate on track (= PARTIAL)
Earnings Call Transcript filed with BSE, NSE: ZYDUSLIFE. Summary written with AI assistance from the document.
Zydus Lifesciences Ltd: key numbers
- Share price
- ₹1,203.90
- Market cap
- ₹1,21,141 Cr
- Revenue (annual)
- ₹27,148 Cr
- Net profit (annual)
- ₹5,040 Cr
- P/E (TTM)
- 26.8×Sector 50.4×
- Promoter holding
- 75.01%+0.01% QoQ
- FII holding
- 6.89%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Zydus Lifesciences Ltd
All →Zydus Lifesciences Business Update
Zydus Lifesciences announced that a recent USFDA inspection of its pharmacovigilance and post-marketing surveillance system at the company’s USA office concluded with nil observations.
Zydus Lifesciences Credit Rating
CRISIL reaffirmed Zydus Lifesciences ratings: CRISIL AAA/Stable (LT) and A1+ (ST) on a Rs.4,724 Cr bank facility, plus CPs and NCDs. The stable outlook signals unchanged strong credit standing.
Zydus Lifesciences Legal & Regulatory
Zydus Lifesciences' subsidiary, ZPUI, settled an antitrust litigation case for a total payment of USD 5.9 million, without admission of wrongdoing.
- Value
- ₹55.46 Cr
Zydus Lifesciences Investor Presentation: Key Takeaways
Zydus Lifesciences reported strong Q1 FY27 revenue growth of 22% YoY, driven by robust performance in India and International formulations, despite a decline in PAT and EBITDA margins.
Zydus Lifesciences Q1 FY27 Results: Net Profit ₹939.8 Cr, Down 35.9% YoY
Zydus Lifesciences Ltd reported revenue from operations of ₹8,017 Cr (+22.0% YoY) and net profit of ₹939.8 Cr (-35.9% YoY) for Q1 FY27.
- Key figure
- Net profit ₹939.8 Cr · -35.9% YoY
Zydus Lifesciences Earnings Call: Key Takeaways
Zydus delivered strong Q4 FY26 results with 16% YoY revenue growth and record 33.7% EBITDA margins, driven by US specialty and India branded formulations.